Cargando…

Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature

Refractory cutaneous manifestations constitute a significant unmet need in patients with cutaneous lupus (CLE), even in the setting of systemic lupus erythematosus (SLE) with otherwise good control of inflammatory manifestations. Anifrolumab, an anti-interferon I receptor monoclonal antibody has rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paolino, Giovanni, Ramirez, Giuseppe A., Calabrese, Chiara, Moroni, Luca, Bianchi, Vittoria Giulia, Bozzolo, Enrica P., Mercuri, Santo Raffaele, Dagna, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669425/ https://www.ncbi.nlm.nih.gov/pubmed/38001905 http://dx.doi.org/10.3390/biomedicines11112904

Ejemplares similares

Anifrolumab for systemic lupus erythematosus
Publicado: (2022)

Anifrolumab for Adolescent Discoid Lupus Erythematosus
por: Shaw, Katharina S., et al.
Publicado: (2023)

Role of Anifrolumab in Refractory Cutaneous Manifestations of Lupus Erythematosus: A Case Series and Literature Review
por: Khan, Muhammad Atif, et al.
Publicado: (2023)

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
por: Felten, Renaud, et al.
Publicado: (2019)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2022)

Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2021)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
por: Almquist, Joachim, et al.
Publicado: (2022)

Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort
por: Gerosa, Maria, et al.
Publicado: (2022)

Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review
por: Liu, Zhihui, et al.
Publicado: (2022)

Cardiac Safety of mRNA-based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis
por: Ramirez, Giuseppe A., et al.
Publicado: (2022)

Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year
por: Ramirez, Giuseppe A., et al.
Publicado: (2021)

Successful treatment of severe chronic cutaneous lupus with anifrolumab: A series of 6 cases
por: Kowalski, Eric H., et al.
Publicado: (2023)

Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
por: Tanaka, Yoshiya
Publicado: (2023)

COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients
por: Ramirez, Giuseppe A., et al.
Publicado: (2020)

Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
por: Morand, Eric F, et al.
Publicado: (2023)

Post-traumatic stress disorder in patients with systemic lupus erythematosus heavily affects quality of life. A cross-sectional web survey-based study
por: Moroni, Luca, et al.
Publicado: (2022)

Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
por: Bruce, Ian N, et al.
Publicado: (2022)

Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
por: Ballew, Nick, et al.
Publicado: (2022)

Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
por: Neupane, Binod, et al.
Publicado: (2023)

OA14 The role of anifrolumab in treating life threatening systemic lupus erythematosus with severe mucocutaneous involvement
por: Baldwin, Christopher, et al.
Publicado: (2023)

Alopecia secondary to severe discoid lupus responding to anifrolumab
por: Han, Shannon, et al.
Publicado: (2023)

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
por: Riggs, Jeffrey M, et al.
Publicado: (2018)

Muco-cutaneous manifestations in HIV infection/AIDS
por: Benea, Vasile, et al.
Publicado: (2014)

The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study
por: Gerosa, Maria, et al.
Publicado: (2022)

Adult-Onset Linear Morphea (en coupe de sabre) of the Face Successfully Treated with Photoactivated Low-Temperature Platelet-Rich Plasma: A Valid Therapeutic Option
por: Mercuri, Santo Raffaele, et al.
Publicado: (2023)

Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea
por: Guery, Romain, et al.
Publicado: (2017)

Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study
por: Chatham, W. Winn, et al.
Publicado: (2021)

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
por: Kalunian, Kenneth C., et al.
Publicado: (2022)

Linear cutaneous lupus erythematosus/discoid lupus erythematosus in an adult
por: Mao, Qiu-Xia, et al.
Publicado: (2017)

Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval
por: Loncharich, Michael F., et al.
Publicado: (2022)

Cutaneous lupus erythematosus: An update
por: Grönhagen, Carina M, et al.
Publicado: (2014)

Pathophysiology of cutaneous lupus erythematosus
por: Achtman, Jordan C, et al.
Publicado: (2015)

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
por: Merrill, Joan T, et al.
Publicado: (2018)

Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept
por: Tarazi, Meera, et al.
Publicado: (2018)

Pilot Study on the Use of the “Monocyte-Rich” Platelet-Rich Plasma in Combination with 1927 nm Fractional and 308 nm Excimer Lasers for the Treatment of Vitiligo
por: Mercuri, Santo Raffaele, et al.
Publicado: (2021)

Reflectance Confocal Microscopy of Skin after the Sting of the Jellyfish Pelagia noctiluca
por: Paolino, Giovanni, et al.
Publicado: (2023)

Cutaneous Toll-like Receptor 9 Pre-Defines Hydroxychloroquine Dosage in Patients with Both Discoid and Subacute Lupus Erythematosus
por: Englert, Karolina A., et al.
Publicado: (2023)

Mixed muco-cutaneous pemphigoid: Clinical and immunological features of 15 cases
por: Janela, Raphaël, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mgulh45pni2b11hkfffjfk9fpg